Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate
Last magenta therapeutics, inc earnings: 8/8 08:00 am
Check Earnings Report
-- Data in non-human primates from C100 program show potent stem and immune cell depletion with anti-CD45 amanitin ADC that is well tolerated at efficacious doses -- -- C200 development candidate, anti-CD117 amanitin ADC, showed potent and selective stem cell depletion and immune system preservation in non-human primates and was well tolerated -- -- Additional poster highlights preclinical data on anti-leukemia survival benefit with C100 and C200 targeted conditioning programs -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company highlighted preclinical research on its targeted conditioning programs in four presentations and posters at the Transplant and Cellular Therapy (TCT) annual meeting.
[Read more]
| Impact snapshot | Event time: | MGTA | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
MGTA alerts
MGTA alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTA alerts
High impacting Magenta Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
MGTA
News
- FDA grants RMAT tag for Magenta cell therapy for inherited metabolic disorders [Seeking Alpha]Seeking Alpha
- Magenta Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to MGTA-456 for the Treatment of Inherited Metabolic DisordersBusiness Wire
- Magenta Therapeutics: Valuation Remains Under Pressure With Lack Of Catalysts, But Promise Remains [Seeking Alpha]Seeking Alpha
- Magenta Therapeutics Inc (NASDAQ: MGTA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating.MarketBeat
- Magenta Therapeutics Inc (NASDAQ: MGTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.MarketBeat
- More
MGTA
SEC Filings
- 9/16/19 - Form 4
- 9/10/19 - Form CT
- 9/4/19 - Form 4
- MGTA's page on the SEC website
- More